Mind, Molecule, Market: Cannabis and Psychedelics in Mental Health
Mental health treatment is shifting fast, and two once-taboo categories now sit at the center of it. Cannabis and psychedelics are moving from the margins toward clinical legitimacy, with mounting evidence supporting their use for anxiety, depression, PTSD, and addiction. For the professionals shaping this space, the convergence of these two industries marks one of the most significant cannabis industry opportunities of the decade.
This session maps where the two sectors intersect, and where they diverge. We'll examine the clinical pipelines advancing cannabinoids and compounds like psilocybin and MDMA, the funding flowing into both, and the cannabis market trends signaling where demand and capital are headed next. You'll see how operators, researchers, and investors are positioning early, before federal frameworks fully catch up.
We'll also confront the hard parts: fragmented regulation, uneven clinical data, reimbursement gaps, and the reputational risk of moving too soon. Our experts translate these challenges into practical strategies, connecting science to commercial reality.
You'll leave this session with an understanding of how mental health is reshaping both fields, and where your next move fits.
Speakers
More Information
Related Sessions
The Cannabinoid Drug Pipeline: From Clinical Trials to Market
Cannabinoid-based pharmaceuticals are moving from promise to practice,…Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the indus…Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session gives pharmaceutical executives, investors, and researchers a perspective of where clinical development stands today and where the real cannabis industry opportunities sit next. Y…Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session gives pharmaceutical executives, investors, and researchers a perspective of where clinical development stands today and where the real cannabis industry opportunities sit next. You'll learn how to navigate the FDA regulatory pathway, structure clinical trials that withstand scrutiny, and align early-stage research with cannabis business compliance expectations. We'll break down the drug development process stage by stage, then turn to commercialization: pricing, payer access, manufacturing scale, and partnership models that bring a cannabinoid drug to patients. By the end, you'll leave with a strategic framework for evaluating pipelines, de-risking development, and timing market entry. Show MoreClick the title to see all detailsShow More
Bridging the Gap: Medical Cannabis Science and Physician Education
Patients are asking about medical cannabis faster than most providers …Patients are asking about medical cannabis faster than most providers can answer. Many physicians never received formal training on cannabinoid science, dosing, drug interactions, or the patchwork of state regulations that shape what they can legally…Patients are asking about medical cannabis faster than most providers can answer. Many physicians never received formal training on cannabinoid science, dosing, drug interactions, or the patchwork of state regulations that shape what they can legally recommend. That knowledge gap leaves clinicians uncertain, patients underserved, and businesses exposed to compliance risk. This session tackles the problem on two fronts. First, we strengthen pro…Patients are asking about medical cannabis faster than most providers can answer. Many physicians never received formal training on cannabinoid science, dosing, drug interactions, or the patchwork of state regulations that shape what they can legally recommend. That knowledge gap leaves clinicians uncertain, patients underserved, and businesses exposed to compliance risk. This session tackles the problem on two fronts. First, we strengthen provider understanding of medical cannabis science and the evolving regulatory landscape, translating dense research and shifting rules into clear, usable guidance. Second, we sharpen patient-provider communication, giving clinicians practical language to discuss benefits, risks, and expectations without overpromising. Along the way, our panelists connect these skills to current cannabis market trends, cannabis business compliance expectations, and the wider cannabis industry opportunities opening for medically informed operators. Attendees will leave ready to lead more confident, evidence-based conversations that protect patients and strengthen the credibility of the entire field. Show MoreClick the title to see all detailsShow More
Borders Without Barriers: Building Global Cannabis Clinical Trials That Scale
Cannabis research no longer stops at national lines. As medical progra…Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical trial collaboration has become the fastest route to credible data, regulatory approval, and commercial s…Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical trial collaboration has become the fastest route to credible data, regulatory approval, and commercial scale. Yet most operators still struggle with mismatched standards, fragmented data-sharing rules, and approval timelines that differ by jurisdiction. This session maps the current global trial land…Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical trial collaboration has become the fastest route to credible data, regulatory approval, and commercial scale. Yet most operators still struggle with mismatched standards, fragmented data-sharing rules, and approval timelines that differ by jurisdiction. This session maps the current global trial landscape and the real obstacles to cross-border partnership: harmonizing pharmaceutical standards, navigating conflicting regulations, and protecting data integrity across regions. You'll see how shared evidence accelerates product development and unlocks new cannabis industry opportunities in markets that demand clinical proof. Drawing on current cannabis market trends, our experts connect research strategy to commercial reality, showing how global collaboration shortens the path from study to shelf. Built for pharmaceutical executives, researchers, and senior operators, this is a strategy-focused discussion with practical, real-world frameworks.Show MoreClick the title to see all detailsShow More